Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00615836 · ClinicalTrials.gov registry record · Phase 3
An Extension Study Investigating the Efficacy and Safety of a Fast-Dissolving ("Melt") Formulation of Desmopressin for the Treatment of Nocturia in Adults
A Phase 3 study of Nocturia, sponsored by Ferring Pharmaceuticals.
- Completed
- Registry status
- Phase 3
- Development phase
- 554
- Enrollment target
- 20
- Study locations
NCT00615836 is a Phase 3 study of Nocturia that has completed, run by Ferring Pharmaceuticals. The registered enrollment target is 554 participants, above the 255-participant average among 9 other Nocturia trials with a reported enrollment target (117% higher). The trial reports 20 study locations across 6 states.
The verdict
NCT00615836, a Phase 3 study of Nocturia, has completed, sponsored by Ferring Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 554 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study was to investigate the long term efficacy and safety of several doses of the Melt formulation of desmopressin in a broad population of adult patients with nocturia.
Conditions Studied
Interventions
- DRUG Desmopressin Melt
Study Locations (20)
California
- Advanced Urology Medical Center - Anaheim
- Impact Clinical Trials - Beverly Hills
- California Professional Research - Newport Beach
- San Diego Uro-Reseach - San Diego
- Radiant Research - Santa Rosa
- West Coast Clinical Research - Tarzana
- Western Clinical Research - Torrance
Florida
- South Florida Medical Research - Aventura
- Women's Health Research Group, LLC - Clearwater
- Radiant Research - St. Petersburg - Pinellas Park
- Sunrise Medical Research - Plantation
- Radiant Research - Stuart
- Tampa Bay Urology - Tampa
- Radiant Research - West Palm Beach
Colorado
- Urology Associates PC - Denver
- Downtown Women's Health Care - Denver
- Genitourinary Surgical Consultants - Denver
Arizona
- Radiant Research - Scottsdale
Arkansas
- Arkansas Primary Care Clinic, PA - Little Rock
Connecticut
- Connecticut Clinical Research Center, LLC - Middlebury
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 554 participants |
| Start Date | 2007-12 |
| Est. Completion | 2010-05 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00615836
The ClinicalTrials.gov registry entry for NCT00615836 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 554 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 255-participant average among 9 other Nocturia trials with a reported enrollment target (117% higher). The listed sponsor is Ferring Pharmaceuticals, which has 83 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Nocturia appearing as the primary indexed condition, and to 1 intervention - of which Desmopressin Melt is the first listed.
NCT00615836 reports 20 study locations spanning 6 distinct geographic areas - top geographies include California, Florida, Colorado.
Frequently Asked Questions
What is clinical trial NCT00615836 about?
NCT00615836 is a clinical study titled "An Extension Study Investigating the Efficacy and Safety of a Fast-Dissolving ("Melt") Formulation of Desmopressin for the Treatment of Nocturia in Adults". The purpose of this study was to investigate the long term efficacy and safety of several doses of the Melt formulation of desmopressin in a broad population of adult patients with nocturia.
What is the current status of trial NCT00615836?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 554 participants. The study started on 2007-12. Estimated completion is 2010-05.
What conditions does trial NCT00615836 study?
This clinical trial studies the following conditions: Nocturia.
What interventions are being tested in trial NCT00615836?
The interventions under investigation include: Desmopressin Melt (DRUG).
Who is sponsoring clinical trial NCT00615836?
This trial is sponsored by Ferring Pharmaceuticals, which has 83 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00615836 being conducted?
This trial has 20 study locations across Arizona, Arkansas, California, Colorado, Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Nocturia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Efficacy and Safety of Desmopressin Melt for the Treatment of Nocturia
COMPLETED · Phase 3
-
Study Investigating the Impact Burden of Nocturia Using the Nocturia Impact Diary
COMPLETED · Phase 3
-
Long Term Safety Assessment of SER120 in Patients With Nocturia
COMPLETED · Phase 3
-
Mandibular Advancement Device and Changes in Nocturia
RECRUITING · NA
-
Post-procedural Pain Associated With 5 Versus 20 Intravesical Injections of Onabotulinumtoxin A
RECRUITING · Phase 4
-
Multi-center Trial to Improve Nocturia and Sleep in Older Adults
RECRUITING · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.